Mar 11, 2020 · Ligand Pharmaceuticals Inc. (LGND) stock is trading at $95.99 as of 2:20 PM on Wednesday, Mar 11, a loss of -$2.13, or -2.17% from the previous closing price of $98.12. The stock has traded between $95.02 and $104.00 so far today. Volume today … LIGAND PHARMACEUTICALS INCORPORATED CASI CASI Pharmaceuticals, Inc. Cardioxyl Cardioxyl Pharmaceuticals, Inc. CI-AKI Contrast-induced acute kidney injury Code of Conduct Code of Conduct and Ethics Policy Coherus Coherus Biosciences, Inc. CoM Composition of Matter Company Ligand Pharmaceuticals Incorporated, including subsidiaries Convertible Note Senior Convertible Promissory Note Ligand Pharmaceuticals Inc (LGND) Q4 2019 Earnings Call ...
View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. Ligand Pharmaceuticals Inc Change company Symbol lookup
LIGAND PHARMACEUTICAL INC (LGNDZ) Interactive Stock Chart ... CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 05/14/2019 at an average price of $113.5 a share. Ligand Pharmaceuticals Incorpor (LGND) Stock Price, Quote ... Find the latest Ligand Pharmaceuticals Incorpor (LGND) stock quote, history, news and other vital information to help you with your stock trading and investing.
LGND Stock | LIGAND PHARMACEUTICALS Stock Price Today ...
8 Jan 2019 Ligand Pharmaceuticals Inc (NASDAQ: LGND) is a biopharmaceutical company focused on developing or acquiring technologies that help View LGND stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. Ligand Pharmaceuticals Incorporated is a company in the U.S. stock market and it is a holding in 74 U.S.-traded ETFs. LGND has around 2.9M shares in the U.S.
Ligand Pharmaceuticals Incorporated Common Stock (LGND) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Ligand Pharmaceuticals Inc (LGND:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. High Risk, High Return - Ligand Has 100% Upside - Ligand ... Feb 28, 2019 · Ligand Pharmaceuticals (NASDAQ:LGND) share price has fallen more than 50% since September, and on January 16, Citron Research published a … Ligand Pharmaceuticals Inc, LGND:NMQ summary - FT.com
Feb 28, 2019 · Ligand Pharmaceuticals (NASDAQ:LGND) share price has fallen more than 50% since September, and on January 16, Citron Research published a …
Ligand Pharmaceuticals Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Ligand Pharmaceuticals Inc’s price can fluctuate throughout the course of each trading day—when you buy Ligand Pharmaceuticals Inc through Comerica Bank Sells 1,208 Shares of Ligand Pharmaceuticals ... Ligand Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $153.17. Ligand Pharmaceuticals stock opened at $102.62 on Thursday. Ligand Pharmaceuticals Inc. has a one year low of $84.45 and a one year high of $130.50. The business’s fifty day moving average is $93.54 and its 200 day moving average is Ligand Pharmaceuticals Inc. (LGND) Largest Owner Sells Shares
View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. Ligand Pharmaceuticals Inc Change company Symbol lookup Ligand Pharmaceuticals Inc : LGND Stock Price Quote at ... Business Description Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Press Releases :: Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March. March 2, 2020. Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales. February 27, 2020. Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen. Ligand Pharmaceuticals Inc (LGND) Q3 2019 Earnings Call ... In this quarter the performance of Viking's share price and the amortization of the purchase price from our Palvella and Novan investments contributed to the loss. The unrealized loss related to the movement in Viking's stock price that's included in our GAAP earnings this quarter was $10.5 million.